These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 31502147)

  • 1. Measuring Tumor Mutational Burden Using Whole-Exome Sequencing.
    Vilimas T
    Methods Mol Biol; 2020; 2055():63-91. PubMed ID: 31502147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genomic scoring to determine clinical benefit of immunotherapy by targeted sequencing.
    Kim HS; Cha H; Kim J; Park WY; Choi YL; Sun JM; Ahn JS; Ahn MJ; Park K; Lee SH
    Eur J Cancer; 2019 Oct; 120():65-74. PubMed ID: 31493723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic.
    Chan TA; Yarchoan M; Jaffee E; Swanton C; Quezada SA; Stenzinger A; Peters S
    Ann Oncol; 2019 Jan; 30(1):44-56. PubMed ID: 30395155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exome Analysis Reveals Genomic Markers Associated with Better Efficacy of Nivolumab in Lung Cancer Patients.
    Richard C; Fumet JD; Chevrier S; Derangère V; Ledys F; Lagrange A; Favier L; Coudert B; Arnould L; Truntzer C; Boidot R; Ghiringhelli F
    Clin Cancer Res; 2019 Feb; 25(3):957-966. PubMed ID: 30154227
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non-Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel.
    Wang Z; Duan J; Cai S; Han M; Dong H; Zhao J; Zhu B; Wang S; Zhuo M; Sun J; Wang Q; Bai H; Han J; Tian Y; Lu J; Xu T; Zhao X; Wang G; Cao X; Li F; Wang D; Chen Y; Bai Y; Zhao J; Zhao Z; Zhang Y; Xiong L; He J; Gao S; Wang J
    JAMA Oncol; 2019 May; 5(5):696-702. PubMed ID: 30816954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of tumor mutational burden: correlation of five large gene panels with whole exome sequencing.
    Heydt C; Rehker J; Pappesch R; Buhl T; Ball M; Siebolts U; Haak A; Lohneis P; Büttner R; Hillmer AM; Merkelbach-Bruse S
    Sci Rep; 2020 Jul; 10(1):11387. PubMed ID: 32647293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of targeted next generation sequencing to characterize tumor mutational burden and efficacy of immune checkpoint inhibition in small cell lung cancer.
    Ricciuti B; Kravets S; Dahlberg SE; Umeton R; Albayrak A; Subegdjo SJ; Johnson BE; Nishino M; Sholl LM; Awad MM
    J Immunother Cancer; 2019 Mar; 7(1):87. PubMed ID: 30922388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer.
    Alborelli I; Leonards K; Rothschild SI; Leuenberger LP; Savic Prince S; Mertz KD; Poechtrager S; Buess M; Zippelius A; Läubli H; Haegele J; Tolnay M; Bubendorf L; Quagliata L; Jermann P
    J Pathol; 2020 Jan; 250(1):19-29. PubMed ID: 31471895
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Measurement of tumor mutational burden (TMB) in routine molecular diagnostics: in silico and real-life analysis of three larger gene panels.
    Endris V; Buchhalter I; Allgäuer M; Rempel E; Lier A; Volckmar AL; Kirchner M; von Winterfeld M; Leichsenring J; Neumann O; Penzel R; Weichert W; Glimm H; Fröhling S; Winter H; Herth F; Thomas M; Schirmacher P; Budczies J; Stenzinger A
    Int J Cancer; 2019 May; 144(9):2303-2312. PubMed ID: 30446996
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of a neoantigen epitope in a melanoma patient with good response to anti-PD-1 antibody therapy.
    Nonomura C; Otsuka M; Kondou R; Iizuka A; Miyata H; Ashizawa T; Sakura N; Yoshikawa S; Kiyohara Y; Ohshima K; Urakami K; Nagashima T; Ohnami S; Kusuhara M; Mitsuya K; Hayashi N; Nakasu Y; Mochizuki T; Yamaguchi K; Akiyama Y
    Immunol Lett; 2019 Apr; 208():52-59. PubMed ID: 30880120
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of commonly used solid tumor targeted gene sequencing panels for estimating tumor mutation burden shows analytical and prognostic concordance within the cancer genome atlas cohort.
    Bevins N; Sun S; Gaieb Z; Thorson JA; Murray SS
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32217764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive analysis of potential immunotherapy genomic biomarkers in 1000 Chinese patients with cancer.
    Zang YS; Dai C; Xu X; Cai X; Wang G; Wei J; Wu A; Sun W; Jiao S; Xu Q
    Cancer Med; 2019 Aug; 8(10):4699-4708. PubMed ID: 31270941
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The predictive power of tumor mutational burden in lung cancer immunotherapy response is influenced by patients' sex.
    Wang S; Zhang J; He Z; Wu K; Liu XS
    Int J Cancer; 2019 Nov; 145(10):2840-2849. PubMed ID: 30972745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach.
    Luchini C; Bibeau F; Ligtenberg MJL; Singh N; Nottegar A; Bosse T; Miller R; Riaz N; Douillard JY; Andre F; Scarpa A
    Ann Oncol; 2019 Aug; 30(8):1232-1243. PubMed ID: 31056702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer.
    Assoun S; Theou-Anton N; Nguenang M; Cazes A; Danel C; Abbar B; Pluvy J; Gounant V; Khalil A; Namour C; Brosseau S; Zalcman G
    Lung Cancer; 2019 Jun; 132():65-71. PubMed ID: 31097096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumour mutational burden as a biomarker for immunotherapy: Current data and emerging concepts.
    Fumet JD; Truntzer C; Yarchoan M; Ghiringhelli F
    Eur J Cancer; 2020 May; 131():40-50. PubMed ID: 32278982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors.
    Cristescu R; Aurora-Garg D; Albright A; Xu L; Liu XQ; Loboda A; Lang L; Jin F; Rubin EH; Snyder A; Lunceford J
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35101941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HLA-I diversity and tumor mutational burden by comprehensive next-generation sequencing as predictive biomarkers for the treatment of non-small cell lung cancer with PD-(L)1 inhibitors.
    Cuppens K; Baas P; Geerdens E; Cruys B; Froyen G; Decoster L; Thomeer M; Maes B
    Lung Cancer; 2022 Aug; 170():1-10. PubMed ID: 35689896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Implications of Circulating Tumor DNA Tumor Mutational Burden (ctDNA TMB) in Non-Small Cell Lung Cancer.
    Chae YK; Davis AA; Agte S; Pan A; Simon NI; Iams WT; Cruz MR; Tamragouri K; Rhee K; Mohindra N; Villaflor V; Park W; Lopes G; Giles FJ
    Oncologist; 2019 Jun; 24(6):820-828. PubMed ID: 30867242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.